In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Robin Winter-Sperry and Robert Kersting, PharmD, Global Head, Scientific Alliances, Novartis, about the need for multi-stakeholder partnerships.
In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Jim Wilkinson, PhD, Vice President, Global & US Medical Affairs, Amgen, about how to develop Medical Affairs talent into tomorrow’s leaders.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.
This Standard and Guidance, a collaboration between MAPS, PhactMI, MILE, is intended to inform learners about the Medical Information (MI) function, strategic direction, and operations across multiple geographies.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.
This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
ChatGPT is disrupting content creation, from term papers to journal articles to online information mills and more. This webinar gathers three thought leaders at the cutting edge of this issue to vision how ChatGPT may augment or, at times, undermine the practice of Medical Affairs in areas such as Medical Information, Omnichannel engagement and more.
In today’s episode, we’ll be looking at considerations for Medical Affairs in Rare Disease and Gene Therapy